Sean Gregory – Managing Director – Sarytogan Graphite (ASX:SGA) through its 100% owned subsiduary company, Ushtogan LLP, is the 100% owner of the Sarytogan Graphite Project. The Sarytogan Graphite Project is located in the Karaganda region of Central Kazakhstan and the exploration concession covers 70 km2. As its name suggests, the Sarytogan Graphite Project is prospective for graphite and a meaningful initial JORC compliance resource has already been delineated on the project.
Copyright 2024 – Finance News Network
01 Dec 2021 - MinRex Resources Limited (ASX:MRR) Non-Executive Director George Karageorge provides an update on the company's gold and base metals projects in WA and the Lachlan Ford Belt, NSW and its recently acquired lithium projects in the Pilbara.
22 Oct 2019 - QEM Limited (ASX:QEM) Executive Director & CEO, David Fitch and GM & Chief Geologist, Scott Drelincourt discuss the company’s Julia Creek vanadium and oil shale tenements in NW QLD, drill results and strategy.
12 Apr 2023 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun discusses recent results, strategy, opportunities post lockdown and milestones ahead.
16 Dec 2019 - Sienna Cancer Diagnostics Limited (ASX:SDX) Managing Director and CEO Carl Stubbings talks about the company's capital raising and co-development of tests using its SIEN-NET liquid biopsies platform technology.
15 Oct 2024 - Nathan Simiana, Director for Industrials and Smart Manufacturing at Deloitte, discusses transforming industry through data-driven decision-making.
25 March 2024 - Altech Batteries Limited (ASX:ATC) Managing Director Iggy Tan provides an update on the company, discussing funding pathways and the results of the DFS.
26 Mar 2024 - Mayfield Group (ASX:MYG) CEO Andrew Rowe provides an overview of the company, discussing its divisions, growth strategy, pipeline of work, dividend policy and outlook.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
